Navigation Links
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
Date:3/26/2008

Forms One of the Largest Sales Teams Promoting a 5-ASA Medicine

BASINGSTOKE, England and PHILADELPHIA, March 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today a co-promotion agreement with TAP Pharmaceutical Products Inc. for LIALDA(TM) (mesalamine) with MMX(R) technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). This three year agreement is for the U.S. only and will add more than 500 additional sales representatives from TAP to increase the reach and frequency of the Shire sales force, which consists of 120 representatives who are currently detailing LIALDA primarily to gastroenterologists.

"Aligning with TAP, one of the most successful and well-respected GI sales organizations in the industry, is a tremendous benefit for Shire as it will quadruple the Lialda sales force across the United States," said Mike Yasick, senior vice president of Shire's Gastrointestinal Business Unit. "With the added expertise of the TAP team, we'll be able to reach more GI specialists as well as primary care providers with messages about Lialda. Shire's GI team has made Lialda the fastest growing brand of mesalamine and with this collaboration we will bolster the frequency of sales calls to our existing base of specialist physicians."

LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Mesalamines are a part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA), a well-established drug of choice and often a first-line treatment for patients with mild to moderate ulcerative colitis.

"Building on the successful introduction of Lialda, which Shire launched in the first quarter of last year, we are excited to work with the Shire team as together
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Whitehouse ... officially joined the Morris County (New Jersey) Chamber ... is a leading business organization in the North ... to further engage some key clients in the ... in the geographic area. Membership enables Whitehouse Laboratories ...
(Date:11/26/2014)... Pittsburgh, PA (PRWEB) November 25, 2014 ... release of its official conference and exposition mobile app, ... available for free download in the App Store for ... as a valuable resource tool before, during and after ... guide containing details on exhibiting companies, technical sessions, Conferee ...
(Date:11/26/2014)... 26, 2014 CURE™ magazine ... on December 5, 2014, in San Francisco prior to ... Heroes event will honor clinicians, caregivers, and advocates who ... neoplasms (MPNs). , Special guest speaker Charles Esten, ... cancer journey at the reception. Over a decade ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... a privately-held biotech company using its proprietary platform technology ... gastrointestinal diseases, announced today that it has elected Christopher ... Inc. to its Board of Directors. ... on our Board," said Dr. Barbara Fox, founder, CEO ...
... Inc. (Nasdaq: SGMO ) today announced that the ... Wednesday, May 2, 2012, after the market closes. The press ... p.m. ET, which will be open to the public via ... review the financial results and discuss other business matters. ...
... 2012 The rise of the corporate ... investing are emerging key themes at BioTrinity, the-premier European ... business network which provides comprehensive support for bioscience businesses ... The first day of the conference saw ...
Cached Biology Technology:Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 3
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... TALLAHASSEE, Fla. -- A groundbreaking paper from a team ... better understanding of how plants could adapt to and ... The research, published in the latest issue of the ... how chromatin (the complex of DNA and proteins) is ... material, so that some genes are turned on and ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... therapy currently used to treat Helicobacter pylori (H. ... disorders, is unsuccessful in around 25 percent of ... Journal of Gastroenterology, finds that adding a bovine ... yield more effective results, with fewer of the ...
... true spontaneity exist ?in fruit flies. This is what ... 16, 2007 issue of the open-access journal PLoS ONE. ... complex robots which only respond to external stimuli," says ... They are assumed to be input-output devices. "When scientists ...
... but don’t count on them to prevent prostate ... Epidemiology, Biomarkers & Prevention, researchers based at the ... Center report that lycopene, an antioxidant predominately found ... In fact, the researchers noted an association ...
Cached Biology News:Do fruit flies have free will? 2No magic tomato? Study breaks link between lycopene and prostate cancer prevention 2
... provides a convenient method to probe conformational changes ... substrates. Thus, the kit may be used to ... as transport substrates for MDR1. Because UIC2 binding ... substrates, the MDR1 Shift Assay can be utilized ...
... wide and long electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5 ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7microns and ... (3-5mm in diameter) in comparison to core ...
Biology Products: